Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

Annals of Neurology

Volumn 76, Issue 2, 2014, Pages 231-240

  Villar, Luisa M ^a   Casanova, Bonaventura ^b   Ouamara, Nadia ^c   Comabella, Manuel ^d   Jalili, Farzaneh ^c   Leppert, David ^e   De Andrés, Clara ^f   Izquierdo, Guillermo ^g   Arroyo, Rafael ^h   Avşar, Timuçin ⁱ   Lapin, Sergey V ^j   Johnson, Trina ^c   Montalbán, Xavier ^d   Fernández, Oscar ^k   Álvarez Lafuente, Roberto ^h   Masterman, Donna ^e   García Sánchez, María I ^g   Coret, Francisco ^l   Siva, Aksel ^m   Evdoshenko, Evgeniy ⁿ   Álvarez Cermeño, José C ^a,o   Bar Or, Amit ^c   more..

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c MCGILL UNIVERSITY   (Canada)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^j PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^k HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^m ISTANBUL UNIVERSITY   (Turkey)

ⁿ City Hospital 8   (Russian Federation)

^o UNIVERSITY OF ALCALÁ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN M; OLIGOCLONAL BAND; PLACEBO; RITUXIMAB;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; SERODIAGNOSIS; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; OLIGOCLONAL BANDS; PHENOTYPE;

EID: 84907598732     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24190     Document Type: Article

References (35)

1. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
2. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis. Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
3. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846.
4. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
5. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
6. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
7. Villar LM, González-Porqué P, Masjuán J, et al. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 2001; 258: 151-155.
8. Sádaba MC, González Porqué P, Masjuan J, et al. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004; 284: 141-145.
9. Miller DH, Leary SM,. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6: 903-912.
10. Antel J, Antel S, Caramanos Z, et al. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012; 123: 627-638.
11. Lassmann H, van Horssen J, Mahad D,. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
12. Imrell K, Landtblom AM, Hillert J, Masterman T,. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006; 67: 1062-1064.
13. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-559.
14. Jongen PJ, Lycklama a Nijeholt G, Lamers KJ, et al. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol 2007; 58: 90-95.
15. Villar LM, García-Sánchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol 2012; 69: 191-197.
16. Kostulas VK, Link H, Lefvert AK,. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 1987; 44: 1041-1044.
17. McLean BN, Luxton RW, Thompson EJ,. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990; 113: 1269-1289.
18. Villar LM, Masjuan J, Sádaba MC, et al. Improved oligoclonal IgG detection for the early diagnosis of multiple sclerosis. Arch Neurol 2005; 62: 574-577.
19. Lourenco P, Shirani A, Saeedi J, et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2013; 19: 577-584.
20. Villar LM, Sádaba MC, Roldán E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
21. Durante L, Zaaraoui W, Rico A, et al. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler 2012; 18: 587-591.
22. Magraner MJ, Bosca I, Simó-Castelló M, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012; 54: 5-12.
23. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53: 222-226.
24. Thangarajh M, Gomez-Rial J, Hedström AK, et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008; 14: 1208-1213.
25. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002; 58: 824-826.
26. Sola P, Mandrioli J, Simone AM, et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 2011; 17: 303-311.
27. Sádaba MC, Tzartos J, Paíno C, et al. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 2012; 247: 86-94.
28. Villar LM, Espiño M, Cavanillas ML, et al. Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clin Immunol 2010; 137: 51-59.
29. Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 2012; 9: 93.
30. Ansel KM, Harris RBS, Cyster JG,. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002; 16: 67-76.
31. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-714.
32. Berland R, Wortis HH,. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20: 253-300.
33. Yanaba K, Bouaziz JD, Haas KM, et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-650.
34. Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491: 264-268.
35. Harrer A, Tumani H, Niendorf S, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 2013; 19: 1209-1212.